Phase I clinical trials represent the first administration of an investigational medicinal product in humans. These early-stage studies focus on evaluating safety, tolerability, dose range and how the drug behaves within the body, forming the scientific foundation for all subsequent development.
PHARMExcel supports phase I trials with a focus on robust study design, intensive safety oversight and high-quality pharmacokinetic (PK) and pharmacodynamic (PD) data generation.
The primary objective of a phase I trial is to understand how a new compound is processed by the human body and to identify dose levels suitable for further investigation. These studies establish critical parameters that guide Phase II development.
Phase I trials typically involve small cohorts of participants, usually between 20 and 80 individuals. Many studies enrol healthy volunteers to assess baseline safety, while patient populations may be included in areas such as oncology or where existing treatment options are limited.
These trials often require intensive monitoring, including frequent clinical assessments and laboratory testing, close observation for adverse reactions and inpatient stays or extended site visits during dosing periods.
Dose escalation studies progress through carefully controlled cohorts, beginning with low doses and increasing incrementally based on predefined safety criteria. Each step is informed by real-time safety and exposure data, ensuring participant wellbeing remains the central priority.
PHARMExcel applies structured escalation models and clear stopping rules to support informed decision-making throughout the trial.
Ethical conduct is central to phase I research. Participants provide informed consent and are fully briefed on potential risks and study procedures. While direct therapeutic benefit is limited, these studies contribute essential knowledge to future patient care.
PHARMExcel ensures phase I trials align with regulatory expectations, ethical standards and Good Clinical Practice (GCP) requirements.
PHARMExcel has extensive relationships with hospital sites and specialist healthcare centres throughout the UK, allowing it to quickly identify the right sites for your study, taking into consideration each site’s experience, trial capacity and its commitment to clinical research.
We specialise in designing and executing early phase studies that drive your drug or medical device closer to patients. Our flexible service offering means you can pick and choose the level of support you need throughout your pipeline development.
We like to start with a conversation to allow you you to see if we’re the right fit for your organisation.
Who takes part in a Phase I clinical trial?
Early Phase clinical trials typically enrol healthy volunteers to evaluate safety and drug behaviour under controlled conditions. In certain therapeutic areas, including oncology and rare diseases, patients with the target condition may be recruited due to clinical or ethical considerations.
How are safety risks managed during phase I clinical trials?
Safety risks are managed through strict eligibility criteria, predefined dosing limits and intensive monitoring. Participants undergo frequent clinical assessments, laboratory testing and adverse event reporting to ensure early identification of potential risks.
What does dose escalation involve in a Phase I study?
Dose escalation involves administering increasing dose levels to small participant cohorts according to a predefined protocol. Progression to higher doses depends on safety data, exposure levels and clearly defined stopping rules.
What type of data is collected during Phase I trials?
Phase I trials generate pharmacokinetic data, including absorption, distribution, metabolism and excretion, alongside pharmacodynamic and safety data. This information supports dose selection and study design for subsequent clinical phases.
Are Phase I clinical trials conducted in hospital settings?
Many phase I trials are conducted in specialist clinical research units or hospital environments. Inpatient stays or extended site visits, are often required to support intensive monitoring during dosing and follow-up periods.
What ethical safeguards are in place for Phase I trial participants?
Phase I trials are conducted under strict ethical oversight, including informed consent processes and independent review by ethics committees. Participants receive clear information about risks, study procedures and their right to withdraw at any time.
Talk to us about our flexible service offering.
